Paper Details

  1. Home
  2. Paper Details

2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants.

Author: ChuChung K, MulamoottilVarughese A, SinghUma S

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

2'-fluoro-6'-methylene carbocyclic adenosine (FMCA) and its phosphoramidate (FMCAP) have shown potential anti-HBV activity against drug-resistant mutants. These carbocyclic NAs may be utilized in combination therapies for curing drug-resistant chronic hepatitis B.
Paper Details　
Original Abstract of the Article :
Chronic hepatitis B (CHB) is one of the major causes of morbidity and mortality worldwide. Currently, clinically approved nucleos(t)ide analogs (NAs) are very efficient in reducing the load of hepatitis B virus (HBV) with minimum side effects. However, the long-term administration of antiviral drugs...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/med.21490

データ提供：米国国立医学図書館（NLM）

Fighting Drug-Resistant Hepatitis B: A New Weapon in the Arsenal

Chronic hepatitis B (CHB) is a major global health problem, with millions of people infected worldwide. While current nucleos(t)ide analogs (NAs) are effective in reducing viral load, the emergence of drug-resistant HBV strains poses a significant challenge. This study introduces two novel carbocyclic NAs, 2'-fluoro-6'-methylene carbocyclic adenosine (FMCA) and its phosphoramidate prodrug (FMCAP), as potential agents against drug-resistant HBV mutants.

A New Oasis in the Fight Against Drug Resistance

Preclinical studies demonstrated that FMCA and FMCAP exhibited potent antiviral activity against adefovir and lamivudine (LMV)-resistant HBV mutants, including triple mutants resistant to both LMV and entecavir (ETV). This suggests that these novel compounds could be valuable additions to combination therapies for treating drug-resistant CHB, providing a new oasis of hope in the battle against this challenging disease.

The Importance of Staying Ahead of the Curve

The emergence of drug resistance is a constant threat in the treatment of viral infections. This study highlights the need for ongoing research and development of novel antiviral agents to stay ahead of evolving viral strains. It's like navigating a desert landscape where the terrain is constantly shifting, requiring adaptability and innovation to overcome new challenges.

Dr.Camel's Conclusion

This study offers a promising new approach to treating drug-resistant CHB. The development of FMCA and FMCAP could significantly enhance our arsenal of antiviral therapies, helping us to navigate the shifting sands of viral resistance and provide effective treatment options for individuals living with CHB.

Date :
  1. Date Completed 2018-11-16
  2. Date Revised 2018-11-16
Further Info :

Pubmed ID

29406612

DOI: Digital Object Identifier

10.1002/med.21490

Related Literature

Article Analysis
・Side Effects of entecavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.